RA
OtherRA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
NCT Number: NCT02880306
Rheumatoid arthritis(RA) is a disorder with altered immunologic function and increased risk of developing malignancies, while studies examining the association between hepatocellular carcinoma (HCC) and RA remain lacking. The investigators aimed to investigate the risk of HCC between participants with and without RA.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Observational
The investigators did a retrospective, observational, nested case-control study in a cohort that was previously recruited from a population-based RA survey. All participants were enrolled prospectively in Taiwan's national health insurance between Jan 1, 1999, and June 30, 2009, and had follow-up data until Dec 31, 2009. RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria. The investigators matched RA and non-RA subjects by propensity score in a 1:1 ratio. The primary outcome was the risk of developing HCC. Cox proportional hazards regression was applied to estimate the hazard ratio (HR) and 95% confidence interval (CI) of HCC for RA and non-RA cohort.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
Time frame: between Jan 1, 1999 and Dec 31, 2009
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01171651
Adenocarcinoma, Carcinoma
Busan, South Korea
View Trial DetailsNCT04962958
Adenocarcinoma, Antimetabolites
Guangzhou, Guangdong, China
View Trial DetailsNCT04102098
Adenocarcinoma, Carcinoma
Los Angeles, California, United States
View Trial DetailsNCT00554372
Adenocarcinoma, Carcinoma
La Jolla, California, United States
View Trial Details